China Next-Gen Commerce and Supply Chain (HKG:3928) recorded SG$5.6 million in attributable loss for the fiscal first half ended March 31, sliding from a profit of SG$413,129 a year earlier, according to a Friday filing with the Hong Kong bourse.
Loss per share was SG$0.0115, compared with SG$0.0009 in the prior-year period.
Revenue fell to SG$16.3 million from SG$32 million a year earlier.
Shares of the construction company fell over 7% in morning trade Monday.
The U.S. Commerce Department released a guideline disallowing the export of the world's most sophisticated chips to subsidiaries of Chinese firms outside China, Reuters reported Sunday.The guidance closes a potential gap that allowed Chinese companies access to the U.S.'s most advanced AI chips, such as Nvidia's Blackwell processors, the newswire said.The guidelines came out after a paper regarding the loophole circulated that said "the floodgates have quietly opened," Reuters said."BIS will continue to enforce export controls rigorously to safeguard critical American technology," the newswire quoted a bureau spokesperson as saying.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
CapitaLand Investment's (SGX:9CI) workforce in China dropped by around 10% in 2025, with the real estate firm impacted by an industry crisis in the region, according to the company's sustainability report published late Saturday.The company's headcount shrunk to 9,542 employees in 2025, compared with 10,158 in the prior period.
Hanmi Pharm (KRX:128940) signed a technology licensing agreement for Sonefpeglutide (HM15912), a short bowel syndrome drug, with Eli Lilly and Co., according to a Monday filing with the Korea Exchange.The technology licensing agreement is worth up to $1.26 billion, including a $75 million upfront payment and up to $1.185 billion in development, regulatory, and commercial milestones, along with royalties based on future sales, the filing said.Shares of Hanmi Pharm rose more than 7% in recent trade.